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CYTOSINE ARABINOSIDE (Ara-C) and 6-
thioguanine (6-TG) are currently used in
many protocols for acute myeloid leu-
kaemia (AML). Clinical results suggest
that the combination is synergistic (Clark-
son, 1972). The chief limitation in the use
of Ara-C is its very short half-life, of the
order of 10 min, which results from the
rapid deamination of the drug. It was
decided to study the effect of each drug
on the metabolic products of the other,
in populations of blast cells from 57
previously untreated patients. This was
an extension of the type of investigation
already reported, and the method employ-
ed was very similar (Smyth et al., 1976).
Briefly the leukaemic blast cells were
prepared from blood or marrow specimens
by lymphoprep sedimentation. They were
saline-washed, suspended in culture med-
ium at 2.106/ml and exposed for 30 min at
37°Cto [3H]Ara-C(25/tM) or [14C]-6-TG (35
,M) or to a mixture of both. After centri-
fugation, pellets were drained free of
supernatant, lOdul N HCI 04 was added
and 2,ul aliquots subjected to high voltage
electrophoresis on paper to separate the
metabolites. The regions corresponding to
Ara-C, AraU the Ara-C phosphates and
the equivalent metabolites of 6-TG were
cut out and estimated by liquid-scintilla-
tion counting. The metabolic products
of one drug were not affected by the
presence of the other with the exception
that in 12/57 cases the production of
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AraU from Ara-C was reduced by 6-TG.
This reduction varied from 20-100%,
suggesting an effect of 6-TG upon Ara-C
deamination. It is known that 6-TG
inhibits some enzymes of nucleic-acid
biosynthesis, but inhibition of cytidine
deaminase has not been reported (Sartor-
elli & Lepage, 1958). Therefore, the kin-
etics of such deamination were investi-
gated. Cells from a suitable blast popula-
tion were diluted with 3 volumes ofwater,
disintegrated by 5 cycles offreeze thawing
and centrifuged at 20,000 g for 1 h. The
supernatant was used as a crude deami-
S
FIG. Plot of Ara-C concentration, S (,UM)
against S/V O uninhibited,
- - - - - inhibited by 200,uM 6-TG.
V = rate of deamination nmol/min/50,u1
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nase preparation to the extent of 50,p1/ml
substrate (Ara-C) at pH 7-5. Ara-C concen-
trations were varied from 50 to 400 uM
and the deamination was stopped after
various times by addition of N HC104.
The extent of deamination was esti-
mated from the extinction at 290 nm
(em (290) Ara-C = 9,6 x 103, AraU =
0*3 x 103). In a separate experiment, 200
pM 6-TG was also added duringincubation.
In the Figure are plotted the data in the
form of S/V versus S plots where S
substrate concentration and V = velocity
ofreaction (nmol/min/50pl enzyme). From
this figure the values of 120IM may be
calculated for Kn, and 170 M for Ki. The
inhibition of deamination by 6-TG is thus
competitive and of the same magnitude
as Km. A value of 120-160pM for Ki for
human liver deaminase has been reported
(Camiener, 1967).
The inhibitory effect of 6-TG upon
cytidine deaminase which has been des-
cribed suggests that the synergistic effect
of the combination of Ara-C and 6-TG
may, in some cases at least, be the result
of an increase in the half-life of Ara-C
brought about by 6-TG. Such an effect
has been reported in mice (Pittillo &
Woolley, 1973). Data of LePage & White-
car (1971) suggest that levels of 15Mm of
6-TG may be maintained for some hours
following a single oral administration
of the drug in human subjects. Measure-
ments could be made of the half-life
of Ara-C during its first administration,
and compared with the half-life in sub-
sequent adminstrations, after several dos-
ages of 6-TG in a combination schedule.
This would show whether the reported
inhibition of deaminase has any clinical
relevance for the scheduling of the two
drugs.
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